Christopher Alafi Biography and Net Worth



Dr. Christopher D. Alafi Ph.D. is an Independent Director of Intra-Cellular Therapies, Inc. Dr. Alafi became a director of the Company following the Merger that occurred in August 2013 and has served on the board of directors of ITI since January 2013. Dr. Alafi has been a Managing Partner of Alafi Capital Company, LLC, a venture capital firm and a principal stockholder of the Company, since 1995. He was previously a Physiology and Anatomy teacher at Santa Monica College, a visiting scholar in the Department of Chemistry at Stanford University and a researcher at DNAX. Dr. Alafi previously served as a director of ISTO Technologies, Coley Pharmaceutical Group, Inc., CyberGold, Inc. and Stereotaxis, Inc. Dr. Alafi received a B.A. in Biology from Pomona College and a D.Phil. in Biochemistry from the University of Oxford.

What is Christopher D. Alafi's net worth?

The estimated net worth of Christopher D. Alafi is at least $29.18 million as of May 27th, 2021. Dr. Alafi owns 346,795 shares of Intra-Cellular Therapies stock worth more than $29,179,331 as of December 19th. This net worth estimate does not reflect any other investments that Dr. Alafi may own. Learn More about Christopher D. Alafi's net worth.

How do I contact Christopher D. Alafi?

The corporate mailing address for Dr. Alafi and other Intra-Cellular Therapies executives is 430 EAST 29TH STREET, NEW YORK NY, 10016. Intra-Cellular Therapies can also be reached via phone at (464) 440-9333 and via email at [email protected]. Learn More on Christopher D. Alafi's contact information.

Has Christopher D. Alafi been buying or selling shares of Intra-Cellular Therapies?

Christopher D. Alafi has not been actively trading shares of Intra-Cellular Therapies over the course of the past ninety days. Most recently, Christopher D. Alafi sold 8,482 shares of the business's stock in a transaction on Thursday, May 27th. The shares were sold at an average price of $40.01, for a transaction totalling $339,364.82. Following the completion of the sale, the director now directly owns 346,795 shares of the company's stock, valued at $13,875,267.95. Learn More on Christopher D. Alafi's trading history.

Who are Intra-Cellular Therapies' active insiders?

Intra-Cellular Therapies' insider roster includes Christopher Alafi (Director), Suresh Durgam (Insider), Michael Halstead (EVP), Lawrence Hineline (CFO), Joel Marcus (Director), Sharon Mates (CEO), Mark Neumann (EVP), Rory Riggs (Director), and Robert Van Nostrand (Director). Learn More on Intra-Cellular Therapies' active insiders.

Are insiders buying or selling shares of Intra-Cellular Therapies?

During the last year, insiders at the biopharmaceutical company sold shares 23 times. They sold a total of 697,694 shares worth more than $49,905,719.27. The most recent insider tranaction occured on December, 4th when CEO Sharon Mates sold 51,000 shares worth more than $4,375,800.00. Insiders at Intra-Cellular Therapies own 2.6% of the company. Learn More about insider trades at Intra-Cellular Therapies.

Information on this page was last updated on 12/4/2024.

Christopher D. Alafi Insider Trading History at Intra-Cellular Therapies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/27/2021Sell8,482$40.01$339,364.82346,795View SEC Filing Icon  
5/24/2021Sell26,575$40.47$1,075,490.25346,795View SEC Filing Icon  
5/21/2021Sell1,100$40.00$44,000.00346,795View SEC Filing Icon  
9/14/2020Buy49,500$29.60$1,465,200.00345,223View SEC Filing Icon  
9/11/2020Buy21,000$28.08$589,680.00
9/10/2019Buy485,000$10.26$4,976,100.00341,223View SEC Filing Icon  
8/30/2019Buy125,000$8.52$1,065,000.00341,223View SEC Filing Icon  
6/12/2019Buy170,000$11.73$1,994,100.00750,106View SEC Filing Icon  
5/14/2019Buy100,000$12.56$1,256,000.00750,106View SEC Filing Icon  
12/29/2017Buy1,001$14.48$14,494.48View SEC Filing Icon  
11/22/2017Buy10,000$15.55$155,500.00744,466View SEC Filing Icon  
11/14/2016Buy34,000$14.50$493,000.00730,529View SEC Filing Icon  
2/29/2016Buy100,000$29.70$2,970,000.00728,828View SEC Filing Icon  
3/11/2015Buy625,000$24.00$15,000,000.00View SEC Filing Icon  
11/28/2014Buy35,000$14.75$516,250.00View SEC Filing Icon  
See Full Table

Christopher D. Alafi Buying and Selling Activity at Intra-Cellular Therapies

This chart shows Christopher D Alafi's buying and selling at Intra-Cellular Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intra-Cellular Therapies Company Overview

Intra-Cellular Therapies logo
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More

Today's Range

Now: $84.14
Low: $83.42
High: $87.95

50 Day Range

MA: $83.28
Low: $73.61
High: $91.57

2 Week Range

Now: $84.14
Low: $62.78
High: $93.45

Volume

709,554 shs

Average Volume

826,286 shs

Market Capitalization

$8.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95